DB17789ExperimentalVaccines
Octovalent O-polysaccharide-toxin A conjugate vaccine is currently being investigated to treat Pseudomonas Aeruginosa infection in patients with cystic fibrosis.
- Also known as
- octavalent Psuedomonas aeruginosa O-polysaccaharide-toxin A conjugate
What you can answer from here — as of July 03, 2026
Which companies are running trials of Octovalent O-polysaccharide-toxin A conjugate vaccine, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account